Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

Recently, apolipoprotein D (apoD), a protein that is involved in the essential polyunsaturated fatty acid (EPUFA) transport and metabolism, and neuronal growth and regeneration was reported to have increased in the postmortem brain and decreased in the serum of schizophrenia patients. We studied the...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia research 2002-11, Vol.58 (1), p.55-62
Main Authors: Mahadik, Sahebarao P, Khan, Mohammad M, Evans, Denise R, Parikh, Vinay V
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adult and adolescent clinical studies
Analysis of Variance
Antipsychotic Agents - therapeutic use
Apolipoprotein D
Apolipoproteins - blood
Apolipoproteins - drug effects
Apolipoproteins D
Arachidonic acid
Biological and medical sciences
Clozapine - therapeutic use
Enzyme-Linked Immunosorbent Assay
Essential fatty acids
Female
First-episode early psychosis
Humans
Lipid peroxidation
Male
Medical sciences
Membrane phospholipids
Middle Aged
Neuropharmacology
Oxidative stress
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Psychotic Disorders - blood
Psychotic Disorders - drug therapy
Schizophrenia
Schizophrenia - blood
Schizophrenia - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, apolipoprotein D (apoD), a protein that is involved in the essential polyunsaturated fatty acid (EPUFA) transport and metabolism, and neuronal growth and regeneration was reported to have increased in the postmortem brain and decreased in the serum of schizophrenia patients. We studied the plasma apoD levels in never-medicated schizophrenic patients at the onset of psychosis and in chronic patients with clozapine treatment. Plasma apoD levels were elevated in never-medicated patients at the first-episode of psychosis compared to normals ( P=0.047). Interestingly, the increase in apoD level was even more significant in chronic patients treated with clozapine compared to normals and first-episode patients ( P=0.008 and P=0.03, respectively). The increased apoD level in never-medicated first-episode patients indicate that this increase probably predates the illness, since the duration of illness was
ISSN:0920-9964
1573-2509
DOI:10.1016/S0920-9964(01)00378-4